Structural Biology/Biochemistry Seminar
Thursday, March 26, 2015 (note weekday change)
11:15 am | 112 KLB
“Enzymatic Transition States in Drug Design and Chemistry”
Professor and Chair, Dept. of Biochemistry
Albert Einstein College of Medicine
Yeshiva University, New York
Member, National Academy of Sciences
Dr. Schramm has created molecules that block key enzymes from functioning. These powerful inhibitors have shown promise in muzzling cancers and bacteria that depend on those key enzymes to grow and spread. Two of those inhibitors have entered clinical trials: one for treating leukemia that does not respond to other therapies and another for possible treatment for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, and for preventing tissue transplant rejection in organ transplantation.
Dr. Schramm’s other recent work includes developing a simple and highly sensitive test to detect ricin, the potent toxin with potential use as a bioterrorism agent. He is also using his enzyme-inhibiting strategy to create novel antibiotics that do not provoke bacterial resistance.